| Literature DB >> 29699963 |
Axel Georg Meender Schäfer1, Christoff Zalpour2, Harry von Piekartz2, Toby Maxwell Hall3, Volker Paelke4.
Abstract
BACKGROUND: Osteoarthritis of the knee is the most common cause for disability and limited mobility in the elderly, with considerable individual suffering and high direct and indirect disease-related costs. Nonsurgical interventions such as exercise, enhanced physical activity, and self-management have shown beneficial effects for pain reduction, physical function, and quality of life (QoL), but access to these treatments may be limited. Therefore, home therapy is strongly recommended. However, adherence to these programs is low. Patients report lack of motivation, feedback, and personal interaction as the main barriers to home therapy adherence. To overcome these barriers, electronic health (eHealth) is seen as a promising opportunity. Although beneficial effects have been shown in the literature for other chronic diseases such as chronic pain, cardiovascular disease, and diabetes, a systematic literature review on the efficacy of eHealth interventions for patients with osteoarthritis of knee is missing so far.Entities:
Keywords: osteoarthritis, knee; telemedicine; exercise; treatment outcome; review; meta-analysis
Mesh:
Year: 2018 PMID: 29699963 PMCID: PMC5945993 DOI: 10.2196/jmir.9465
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. OAK: osteoarthritis of the knee.
Figure 2Risk of bias summary.
Figure 3Forest plot outcome pain short-term.
Figure 4Forest plot outcome pain long-term.
Figure 5Forest plot outcome function short-term.
Figure 6Forest plot outcome function long-term.
Figure 7Forest plot outcome quality of life short-term.
Figure 8Forest plot outcome quality of life long-term.
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) evidence profile. QoL: quality of life. RCT: randomized controlled trial.
| Outcome | Quality assessment | ||||||
| Number of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | |
| Pain short term (follow-up: range 1 month to 6 months; assessed with self-report questionnaire 0-100 (higher numbers=more pain) | 6 | RCT | Seriousa | Seriousb | Not serious | Not serious | None |
| Pain long term (follow-up: range 9 months to 12 months; assessed with self-report questionnaire 0-100 (higher numbers=more pain) | 3 | RCT | Seriousa,c | Not serious | Not serious | Not serious | None |
| Physical function short term (follow-up: range 1 month to 6 months; assessed with self-report questionnaire 0-100; higher numbers=better function) | 4 | RCT | Seriousa,c | Seriousb | Not serious | Not serious | None |
| Physical function long term (follow-up: range 9 months to 12 months; assessed with self-report questionnaire 0-100; higher numbers=better function) | 3 | RCT | Not serious | Not serious | Not serious | Not serious | None |
| QoL short term (follow-up: range 3 months to 6 months; assessed with self-report questionnaire 0-100; higher numbers=better QoL) | 4 | RCT | Seriousa | Not serious | Not serious | Not serious | None |
| QoL long term (follow-up: range 9 months to 12 months; assessed with self-report questionnaire 0-100; higher numbers=better QoL) | 3 | RCT | Not serious | Not serious | Not serious | Not serious | None |
aSerious risk of bias across studies because of missing blinding of therapists, patients, and outcome assessors.
bHeterogeneity was high with I2 >50%.
cRandomization or allocation procedure unclear for some studies.
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) summary of findings. QoL: quality of life. SMD: standardized mean difference.
| Outcome | Number of patients | Effect | Quality | Importance | ||
| Electronic health–supported exercise | No or other intervention | Relative (95% CI) | Absolute (95% CI) | |||
| Pain short term (follow-up: range 1 month to 6 months; assessed with self-report questionnaire 0-100 (higher numbers=more pain) | 367 | 361 | –a | SMD 0.31 SD lower (0.04 lower to 0.58 lower) | ++oo Low | Important |
| Pain long term (follow-up: range 9 months to 12 months; assessed with self-report questionnaire 0-100 (higher numbers=more pain) | 212 | 204 | – | SMD 0.3 SD lower (0.07 lower to 0.53 lower) | +++o Moderate | Critical |
| Physical function short term (follow-up: range 1 months to 6 months; assessed with self-report questionnaire 0-100; higher numbers=better function) | 243 | 236 | – | SMD 0.3 SD higher (0.17 lower to 0.76 higher) | ++oo Low | Important |
| Physical function long term (follow-up: range 9 months to 12 months; assessed with self-report questionnaire 0-100; higher numbers=better function) | 211 | 205 | – | SMD 0.41 SD higher (0.17 higher to 0.64 higher) | ++++ High | Critical |
| QoL short term (follow-up: range 3 months to 6 months; assessed with self-report questionnaire 0-100; higher numbers=better QoL) | 227 | 219 | – | SMD 0.24 SD higher (0.05 higher to 0.43 higher) | +++o Moderate | Important |
| QoL long term (follow-up: range 9 months to 12 months; assessed with self-report questionnaire 0-100; higher numbers=better QoL) | 211 | 204 | – | SMD 0.27 SD higher (0.06 higher to 0.47 higher) | ++++ High | Critical |
aIndicates "not applicable".
Data and analysis.
| Outcome | Studies | Participants | Statistical method | Effect estimate | |
| 6 | 742 | SMDa (IV, Random, 95% CI) | −0.31 (−0.58 to −0.04) | ||
| 1.1.1 mobile health (mHealth) | 3 | 516 | SMD (IV, Random, 95% CI) | −0.55 (−0.81 to −0.28) | |
| 1.1.2 Telephone | 3 | 226 | SMD (IV, Random, 95% CI) | −0.04 (−0.30 to 0.22) | |
| 3 | 416 | SMD (IV, Random, 95% CI) | −0.30 (−0.53 to −0.07) | ||
| 1.2.1 mHealth | 2 | 280 | SMD (IV, Random, 95% CI) | −0.34 (−0.72 to 0.03) | |
| 1.2.2 Telephone | 1 | 136 | SMD (IV, Random, 95% CI) | −0.22 (−0.56 to 0.11) | |
| 4 | 479 | SMD (IV, Random, 95% CI) | −0.30 (−0.17 to 0.76) | ||
| 1.3.1 mHealth | 2 | 303 | SMD (IV, Random, 95% CI) | 0.66 (0.18 to 1.13) | |
| 1.3.2 Telephone | 2 | 176 | SMD (IV, Random, 95% CI) | —0.13 (−0.81 to 0.55) | |
| 3 | 416 | SMD (IV, Random, 95% CI) | 0.41 (0.17 to 0.64) | ||
| 1.4.1 mHealth | 2 | 280 | SMD (IV, Random, 95% CI) | 0.46 (0.08 to 0.84) | |
| 1.4.2 Telephone | 1 | 136 | SMD (IV, Random, 95% CI) | 0.31 (−0.03 to 0.65) | |
| 4 | 496 | SMD (IV, Random, 95% CI) | 0.24 (0.05 to 0.43) | ||
| 1.5.1 mHealth | 2 | 304 | SMD (IV, Random, 95% CI) | 0.27 (0.04 to 0.49) | |
| 1.5.2 Telephone | 2 | 192 | SMD (IV, Random, 95% CI) | 0.13 (−0.35 to 0.61) | |
| 3 | 415 | SMD (IV, Fixed, 95% CI) | 0.27 (0.06 to 0.47) | ||
| 1.6.1 mHealth | 2 | 279 | SMD (IV, Random, 95% CI) | 0.24 (−0.10 to 0.57) | |
| 1.6.2 Telephone | 1 | 136 | SMD (IV, Random, 95% CI) | 0.33 (0.00 to 0.67) | |